Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:RE:RE:RE:RE:SP after last trial readout

[themagicbox]

Im going to jump in here:

Yes they are at a crossroads, every biotech hits these crossroads. Investors invest in biotech for these crossroad. Derisking or failure is the name of the game, you say you understand biotech investing you should understand that. The point was everything before the GI safety readout was much more horrible for investors, much more painful, much more uncertain but it was all necessary to get to this crossroads.

no substance to this comment whatsoever. Pez's comments appears to beware of the illusion of strength vs weakness. 
Your still focused on the wrong details. FE WILL HAPPEN. Within reasonable boundaries that market doesn't care on the exact date, as evidenced by all the vol and SP rise over this period of uncertainty. What matters is what matters after FE, in my opinion you're still too short-sighted to see that.

She never said it wouldn't. He said its likely to get a delay based on calling the clinics. I can personally attest to that. But go ahead and call the clinics yourself. Thats the most definitive thing to do to prove her/me wrong.

The science has happened because of the management. They were in a cesspit after Ph1, crawling out of that is never going to look pretty. Most biotech never get to comeback from a hit that big, they never get to finish the job. Managements persistence got us to this point. I'm not going to knock them for getting dirty and getting the job done.

The science did not happen because of the management lol. The recovery happened because of the management. This is more of a "I'm having the last word" comment.

I get it your investment thesis is "I'm invested in this pile of trash" .I get it, I don't understand it but I get it. Thanks for sharing.

You can't read minds Qwerty. Just chill and let the chips fall where they may.

Like MUGS said all we can do is take bets. And I'm (and clearly Pez as well) betting a delay in FE. So once again, buy the dip people. 

qwerty22 wrote:

 

Inthepez wrote: ill reply to your comments one by one:

re the ph1 trial. Yes there is a CRO involved from Montreal at that point. ATE however was heavily involved in the recruitment and provided financial incentive to enroll without placing the criteria of the subject most not be enrolled in multiple studies. That was ATE’s fault.

So you admit to one falsehood and then you immediately follow it with another. There was an exclusion for anybody who had participated in trials in the prior 28 days. You're clearly a source for unreliable info

https://clinicaltrials.gov/ct2/show/NCT03220633?term=Antibe&draw=2&rank=3

re it’s “strongest point”. They are at a cross road. They will either fail with severe consequences or pass with great opportunities ahead. Being at their strongest point, also looks like being at their brink of weakest point at the same time i.e. make or break. However, they have an acid test value of 1.07 not bad but not great. They can cover most liabilities. That came at high cost of dilution. 

 

Yes they are at a crossroads, every biotech hits these crossroads. Investors invest in biotech for these crossroad. Derisking or failure is the name of the game, you say you understand biotech investing you should understand that. The point was everything before the GI safety readout was much more horrible for investors, much more painful, much more uncertain but it was all necessary to get to this crossroads.

Re looking backwards lol. I have called a lot clinics after magicbox posted the list. So looking forward I expect a delay since most haven’t met their quota. And the ones that did are no longer recruiting. ATE however has not posted the details of the 5 extra recruitment sites from their last NR. So I can’t follow up on that. 

Your still focused on the wrong details. FE WILL HAPPEN. Within reasonable boundaries that market doesn't care on the exact date, as evidenced by all the vol and SP rise over this period of uncertainty. What matters is what matters after FE, in my opinion you're still too short-sighted to see that.

Re talking about the “value proposition ahead of us”. Bottom line, I wouldnt be invested heavily in ATE if I didn’t think their was a major upside, but that value is in the SCIENCE not the management. And I keep saying that lately so that the criticism tempers the unrealistic optimism that keeps floating on this board. 

The science has happened because of the management. They were in a cesspit after Ph1, crawling out of that is never going to look pretty. Most biotech never get to comeback from a hit that big, they never get to finish the job. Managements persistence got us to this point. I'm not going to knock them for getting dirty and getting the job done.

Consider my comments the counterforce to the sometimes unbridled enthusiasm that’s so prevalent here. 

I get it your investment thesis is "I'm invested in this pile of trash" .I get it, I don't understand it but I get it. Thanks for sharing.

Thougths magicbox? 

 

qwerty22 wrote:

You try to get people to invest millions of dollars in an almost dead company and then tell me you'll be doing that on favourable terms. Funding for this project has been tight and difficult and painful but it's got us to this point. Investors like me (and Mug) have seen our investments increase many times by patiently taking that pain.

You're just plain wrong about Ph1, it was managed by a CRO.

You're here criticizing this company now at the point in its history when it's at its strongest.

You're looking backwards when all the rest of the market is looking forwards.

It really doesn't matter how they got to this point, whether you think they are trash and I think they are geniuses. What matters is the next milestone. That determines whether we end up poorer or richer.

Why do you never talk about the value proposition that lies in front of us?

 

Inthepez wrote: Lol in a world with only one variable you’d be a genius haha. Yes delay but more importantly: cash infusions (how many times have they said cash on hand for ph2c, only to dilute further), private placement, they didn’t outsource the recruitment trial in phase 1 hence the plummet from .8 to .02 etc ...the list goes on.
 

 

AntibeTribe wrote:
I believe what Pez's hyper critical assement of the management is in reference to the delays we have experienced already, which is hilarious if you ask me.